Novan to Present at the Virtual Investor KOL Roundtable
October 21 2020 - 9:00AM
Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today
announced that members of management will participate in the
Virtual Investor KOL Roundtable on Tuesday, October 27, 2020 at
12:00 PM ET.
Participating in the KOL Roundtable discussion
will be Paula Brown Stafford, Chairman and Chief Executive Officer
of Novan and Carri Geer, SVP, Chief Technology Officer of Novan.
Joining the Novan Management team for the roundtable will be John
Browning, MD, FAAD, FAAP, MBA, Clinical Assistant Professor of
Pediatrics and Dermatology at Baylor College of Medicine and at the
University of Texas Health Science Center at San Antonio, Chief of
Dermatology at the Children's Hospital of San Antonio.
A live video webcast of the KOL roundtable
discussion will be available on the Events page of the Investors
section of the Company’s website (novan.com). A webcast replay will
be available two hours following the live presentation and will be
accessible for one year.
In addition to the KOL roundtable discussion,
members of the management team will be available for one-on-one
meetings with qualified members of the investment community. To
schedule a one-on-one call with management, please submit a request
through the conference website virtualinvestorco.com, or contact
the conference at info@virtualinvestorco.com. For more information
about the event, please visit virtualinvestorco.com.
About NovanNovan, Inc. is a
clinical development-stage biotechnology company focused on
leveraging its proprietary nitric oxide (NO) based technology
platform, NITRICIL™ to generate macromolecular New Chemical
Entities (NCEs) to treat multiple indications in dermatology, men’s
and women’s health, infectious diseases and gastroenterology
conditions with significant unmet needs. The Company’s lead product
candidate, SB206, a topical antiviral gel, for the treatment of
molluscum contagiosum, is currently being evaluated in the
B-SIMPLE4 pivotal Phase 3 clinical study. The Company believes that
SB206 as a topical, at-home, caregiver-applied therapy with a rapid
treatment benefit, if approved, would address an important
patient-care need for the treatment of molluscum.
INVESTOR AND MEDIA
CONTACT:
Jenene Thomas JTC Team,
LLC833-475-8247NOVN@jtcir.com
Novan (NASDAQ:NOVN)
Historical Stock Chart
From Apr 2024 to May 2024
Novan (NASDAQ:NOVN)
Historical Stock Chart
From May 2023 to May 2024